GlassScriptPhysician profile
Emilio Sulpizio
NPI 1730543117
$2,196.10
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $602 · 2020: $661 · 2021: $634 · 2022: $264 · 2023: $34.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $34.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $34.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $262.88 | 2019-2022 | |
| Amgen INC. | $259.29 | 2019-2021 | |
| Lilly USA, LLC | $160.99 | 2019-2021 | |
| Incyte Corporation | $148.42 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $147.77 | 2019-2020 | |
| Emd Serono, INC. | $95.36 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.17 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $76.11 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $69.92 | 2019-2020 | |
| Karyopharm Therapeutics INC. | $63.84 | 2022-2023 | Xpovio |
| Glaxosmithkline, LLC. | $60.92 | 2021 | |
| Abbvie INC. | $53.13 | 2019-2020 | |
| Foundation Medicine, INC. | $49.35 | 2020 | |
| Seagen INC. | $49.11 | 2020-2021 | |
| Deciphera Pharmaceuticals INC. | $45.16 | 2021 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $42.87 | 2020-2021 | |
| Dova Pharmaceuticals | $39.90 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.22 | 2019-2021 | |
| Astellas Pharma US INC | $38.14 | 2020-2021 | |
| Celgene Corporation | $36.81 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $28.32 | 2022 | |
| Puma Biotechnology, INC. | $28.05 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $26.07 | 2019-2021 | |
| Kite Pharma, INC. | $25.02 | 2020 | |
| Jazz Pharmaceuticals INC. | $22.95 | 2020 | |
| Blueprint Medicines Corporation | $22.58 | 2021 | |
| Partner Therapeutics, INC. | $22.44 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $22.19 | 2019 | |
| Amag Pharmaceuticals, INC. | $21.40 | 2019 | |
| Acrotech Biopharma INC. | $20.33 | 2021 | |
| Daiichi Sankyo INC. | $20.01 | 2021 | |
| Beigene USA, INC. | $20.00 | 2021 | |
| Kyowa Kirin, INC. | $19.47 | 2020 | |
| Eisai INC. | $16.92 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.92 | 2019 | |
| Aurobindo Pharma USA, INC. | $14.33 | 2020 | |
| Janssen Pharmaceuticals, INC | $13.67 | 2019 | |
| Janssen Biotech, INC. | $12.00 | 2020 | |
| Secura Bio, INC. | $7.07 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emilio Sulpizio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.